EFFICACY AND SAFETY OF ESKETAMINE NASAL SPRAY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND ACTIVE SUICIDAL IDEATION: RESULTS FROM A RANDOMIZED DOUBLE-BLIND STUDY
DOI:
https://doi.org/10.48047/en272v57Keywords:
Major depressive disorder, Suicidal ideation, Esketamine, Rapid-acting antidepressant , NMDA receptor antagonistAbstract
Major depressive disorder and the presence of active suicidal ideation is a psychiatric emergency that must be treated swiftly and efficiently. The traditional antidepressants have the disadvantage of slow action that causes an unmet clinical need in acute suicidal crisis. It was a randomized, placebo-controlled, double-blind study, which compared the effectiveness and safety of the esketamine nasal spray in patients with major depressive disorder and intent-to-committ suicide thoughts. One hundred and sixty (160) patients were randomly assigned to take esketamine 84 mg and the standard-of-care or placebo and standard-of-care. The main outcome measure was Montgomery-Aseberg Depression Rating Scale (MADRS) total score at 24 hours of first dose. The secondary endpoints were modifications to the severity of suicidality and safety outcomes. Esketamine was shown to respond with rapid response in the depressive symptoms than that of placebo, with a statistically significant response in terms of suicidality measures. Adverse events emerging during the treatment were high in the esketamine group yet were mostly mild to moderate and temporary. These results justify the use of esketamine as a suitable and convenient rapid-acting intervention, in high-risk patients with depression.
Downloads
References
World Health Organization. Depression. WHO website: https://www.who.int/news-room/fact-sheets/detail/depression/. March 2018. Accessed October 24, 2019.
Harris EC, Barraclough B. Suicide as an outcome for mental disorders: a meta-analysis. Br J Psychiatry. 1997;170(3):205-228.
Kessler RC, Berglund P, Borges G, et al. Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001-2003. JAMA. 2005;293(20):2487-2495.
Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75(4):336-346.
Holma KM, Melartin TK, Haukka J, et al. Incidence and predictors of suicide attempts in DSM-IV major depressive disorder: a five-year prospective study. Am J Psychiatry. 2010;167(7):801-808.
Blair-West GW, Cantor CH, Mellsop GW, et al. Lifetime suicide risk in major depression: sex and age determinants. J Affect Disord. 1999;55(2-3):171-178.
Bickley H, Hunt IM, Windfuhr K, et al. Suicide within two weeks of discharge from psychiatric inpatient care: a case-control study. Psychiatr Serv. 2013;64(7):653-659.
McAuliffe CM. Suicidal ideation as an articulation of intent: a focus for suicide prevention? Arch Suicide Res. 2002;6(4):325-338.
Deisenhammer EA, Ing CM, Strauss R, et al. The duration of the suicidal process: how much time is left for intervention between consideration and accomplishment of a suicide attempt? J Clin Psychiatry. 2009;70(1):19-24.
Montgomery SA, Dunner DL, Dunbar GC. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol. 1995;5(1):5-13.
Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry. 2007;164(7):1029-1034.
Wasserman D, Rihmer Z, Rujescu D, et al; European Psychiatric Association. The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. Eur Psychiatry. 2012;27(2):129-141.
Valenstein M, Kim HM, Ganoczy D, et al. Higher-risk periods for suicide among VA patients receiving depression treatment: prioritizing suicide prevention efforts. J Affect Disord. 2009;112(1-3):50-58.
Spravato (esketamine) nasal spray [package insert]. Janssen Pharmaceuticals Companies, Titusville, NJ; 2019.
Spravato (esketamine) nasal spray EMA Summary of Product Characteristics. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf.
Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68-72.
Ballard ED, Luckenbaugh DA, Richards EM, et al. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. J Psychiatr Res. 2015;68:68-73.
Ionescu DF, Swee MB, Pavone KJ, et al. Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study. J Clin Psychiatry. 2016;77(6):e719-e725.
Murrough JW, Soleimani L, DeWilde KE, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015;45(16):3571-3580.
Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327-335.
Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175(7):620-630.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Fifth Edition. Washington, DC: American Psychiatric Association; 2013.
Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57.
Williams JB, Kobak KA. Development and reliability of a structured interview guide for the Montgomery-Asberg Depression Rating Scale (SIGMA). Br J Psychiatry. 2008;192(1):52-58.
Alphs L, Fu D-J, Williamson D, et al. Validation and mapping of the Suicidal Ideation and Behavior Assessment Tool (SIBAT). (abstract W88) Neuropsychopharmacology. 2018;43:S427-S428.
Bremner JD, Krystal JH, Putnam FW, et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998;11(1):125-136.
Chernik DA, Gillings D, Laine H, et al. Validity and reliability of the Observer’s Assessment of Alertness/Sedation Scale: study with intravenous midazolam. J Clin Psychopharmacol. 1990;10(4):244-251.
Ballard ED, Snider SL, Nugent AC, et al. Active suicidal ideation during clinical antidepressant trials. Psychiatry Res. 2017;257:303-308.
Leuchter AF, Hunter AM, Tartter M, et al. Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression. Br J Psychiatry. 2014;205(6):443-449.
Wilkinson ST, Ballard ED, Bloch MH, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175(2):150-158.
Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry. 2013;170(7):723-733.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Dr. Vidhya Joth N (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
